2025/03/28 更新

写真a

サノ　ユウタ
佐野　優太
SANO Yuta
所属
医学部附属病院 泌尿器科 助教
大学院担当
大学院医学系研究科
職名
助教

経歴 2

  1. 名古屋大学   大学院医学系研究科

    2024年4月 - 現在

  2. 名古屋大学   医学部附属病院 泌尿器科   助教

    2022年4月 - 現在

経歴の先頭へ▲
 

論文 12

  1. A case of non-traumatic rectus sheath hematoma in a post-kidney transplant patient undergoing catheter embolization during anticoagulation treatment for atrial fibrillation

    Fujieda, K; Saito, S; Tanaka, A; Furuhashi, K; Ozeki, T; Yasuda, Y; Sano, Y; Ishida, S; Maruyama, S

    CEN CASE REPORTS   13 巻 ( 6 ) 頁： 528 - 533   2024年12月

    　詳細を見る

    記述言語：英語   出版者・発行元：CEN Case Reports  

    A 65-year-old man, a post living donor kidney transplant patient, was admitted to the intensive care unit (ICU) with a severe bacterial infection. He also tested positive for coronavirus disease and had a cough. On admission, heparin was administered for atrial fibrillation. On the third day of hospitalization, his general condition had recovered, and he was discharged from the ICU to the general ward. On the fourth day of hospitalization, he experienced abdominal pain, and a hard mass was palpated in the left lower abdomen. On the fifth day of hospitalization, contrast-enhanced computed tomography showed an extensive rectus sheath hematoma (RSH) extending from the left lower abdominal wall to the left side of the bladder, with extravasation from a small branch of the left inferior epigastric artery. Heparin was discontinued, and transcatheter arterial embolization was performed to control the bleeding. RSH is a rare disease, and cases of extensive hematoma in post-kidney transplant patients occur even less frequently. Patients taking anticoagulants and those with chronic kidney disease are at high risk for RSH, so physicians should be cognizant of this disease when these patients develop abdominal pain.

    DOI： 10.1007/s13730-024-00890-2

    Web of Science

    Scopus

    PubMed

  2. A case of late-onset organizing pneumonia following COVID-19 infection in a post-kidney transplant patient

    Fujieda, K; Saito, S; Tanaka, A; Furuhashi, K; Yasuda, Y; Sano, Y; Kato, M; Maruyama, S

    CEN CASE REPORTS   13 巻 ( 5 ) 頁： 346 - 350   2024年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：CEN Case Reports  

    A 50-year-old man who had undergone a living-donor kidney transplant 12 years prior for chronic renal failure due to autosomal dominant polycystic kidney disease contracted coronavirus disease 19 (COVID-19). He had a positive antigen test, mild symptoms, sore throat, and fever of 37.9 ℃. The patient was treated with molnupiravir for 5 days, and the symptoms disappeared 5 days after onset. However, 10 days after onset, he developed a fever of approximately 37 ℃ and a non-productive cough; 27 days after onset, the patient was hospitalized for anorexia and a worsening respiratory condition. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test results on admission were negative, and no antiviral medications were administered against SARS-CoV-2. Computed tomography revealed extensive ground-glass opacities in both lung fields. The patient was treated with steroid pulse therapy, ceftriaxone, atovaquone, azithromycin, and respiratory management using a high-flow nasal cannula. The combined therapies were successful, and the patient was managed with a nasal oxygen cannula after 3 days. Oxygen administration was discontinued after 6 days of hospitalization, and the patient was discharged after 14 days. Based on the laboratory findings, bacterial, interstitial, and Pneumocystis pneumonia were unlikely. The success of the steroid pulse therapy suggested that respiratory failure was caused by pneumonia due to the immune response after COVID-19 infection.

    DOI： 10.1007/s13730-023-00849-9

    Web of Science

    Scopus

    PubMed

  3. Changes in antibody titer after four and five doses of the SARS-CoV-2 vaccine in Japanese post-kidney transplant patients

    Fujieda, K; Tanaka, A; Kikuchi, R; Takai, N; Saito, S; Yasuda, Y; Sano, Y; Kato, M; Furuhashi, K; Maruyama, S

    THERAPEUTIC APHERESIS AND DIALYSIS   28 巻 ( 4 ) 頁： 489 - 498   2024年8月

    　詳細を見る

    記述言語：英語   出版者・発行元：Therapeutic Apheresis and Dialysis  

    Introduction: Immunosuppressed patients exhibit low antibody acquisition rates following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Kidney transplant recipients previously exhibited low antibody acquisition rates after two vaccine doses, which increased after the third dose. We evaluated antibody titers of Japanese post-kidney transplant patients after the fourth and fifth vaccinations. Methods: Antibody titers for SARS-CoV-2 spike protein were measured between 3 weeks and 3 months after the fourth or fifth vaccination. Results: Increased antibody acquisition rates were observed after the fourth (75.0% antibody-positive) and fifth (81.5% antibody-positive) vaccinations. The antibody-acquired group after the fourth vaccination exhibited a higher body mass index and estimated glomerular filtration rate (eGFR) than the non-acquired group. A higher eGFR was associated with antibody acquisition after the fifth vaccination. Conclusion: In Japanese post-kidney transplant patients, the antibody acquisition rate increased with each vaccine additional dose. Additional vaccinations are recommended to protect against SARS-CoV-2 infection.

    DOI： 10.1111/1744-9987.14114

    Web of Science

    Scopus

    PubMed

  4. Optimal sequential therapy for metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors in the up-front era.

    Naito, Y; Nagayama, J; Sano, Y; Inoue, S; Matsuo, K; Sano, T; Ishida, S; Matsukawa, Y; Kato, M; Akamatsu, S

    JOURNAL OF CLINICAL ONCOLOGY   42 巻 ( 4_SUPPL ) 頁： 168 - 168   2024年2月

    　詳細を見る

  5. Establishment of an adverse effect prevention protocol on plasma exchange using fresh frozen plasma prior to ABO-incompatible living donor kidney transplantation at our hospital

    Tanaka, A; Watanabe, Y; Furuhashi, K; Saito, S; Yasuda, Y; Kosugi, T; Sano, Y; Kato, M; Maruyama, S

    THERAPEUTIC APHERESIS AND DIALYSIS   28 巻 ( 1 ) 頁： 152 - 157   2024年2月

    　詳細を見る

    記述言語：英語   出版者・発行元：Therapeutic Apheresis and Dialysis  

    Introduction: Simple plasma exchange (PE) with fresh-frozen plasma replacement allows antibody removal for ABO-incompatible living donor kidney transplantation, but is associated with a high incidence of allergic reactions. We developed, implemented, and evaluated a protocol for safe preoperative PE. Methods: The protocol comprised pretreatment (125 mg methylprednisolone infusion, 400 mg acetaminophen and 30 mg diphenhydramine orally) with a replacement fluid rate < 20 mL/min. Allergic reaction incidence was investigated in controls who underwent ABO-incompatible living donor kidney transplantation between 2016 and March 2020 (group C) and patients who underwent the protocol and procedure between April 2020 and February 2023 (group N). Results: Ten (group C) and 19 (group N) patients performed 11 and 30 sessions of PE, respectively. Allergic reactions occurred in 81.8% and 36.7% (p = 0.014), respectively, with an odds ratio of the protocol was 0.056 (95% CI 0.0059–0.5380, P = 0.013). Conclusion: Our protocol resulted in a significantly lower incidence of allergic reactions.

    DOI： 10.1111/1744-9987.14071

    Web of Science

    Scopus

    PubMed

  6. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate Open Access

    Naito, Y; Kato, M; Nagayama, J; Sano, Y; Matsuo, K; Inoue, S; Sano, T; Ishida, S; Matsukawa, Y; Tsuzuki, T; Akamatsu, S

    INTERNATIONAL JOURNAL OF UROLOGY   31 巻 ( 1 ) 頁： 7 - 16   2024年1月

    　詳細を見る

    記述言語：英語   出版者・発行元：International Journal of Urology  

    Intraductal carcinoma of the prostate, a unique histopathologic entity that is often observed (especially in advanced prostate cancer), is characterized by the proliferation of malignant cells within normal acini or ducts surrounded by a basement membrane. Intraductal carcinoma of the prostate is almost invariably associated with an adjacent high-grade carcinoma and is occasionally observed as an isolated subtype. Intraductal carcinoma of the prostate has been demonstrated to be an independent poor prognostic factor for all stages of cancer, whether localized, de novo metastatic, or castration-resistant. It also has a characteristic genetic profile, including high genomic instability. Recognizing and differentiating it from other pathologies is therefore important in patient management, and morphological diagnostic criteria for intraductal carcinoma of the prostate have been established. This review summarizes and outlines the clinical and pathological features, differential diagnosis, molecular aspects, and management of intraductal carcinoma of the prostate, as described in previous studies. We also present a discussion and future perspectives regarding intraductal carcinoma of the prostate.

    DOI： 10.1111/iju.15299

    Web of Science

    Scopus

    PubMed

  7. Treatment escalation and de-escalation of de-novo metastatic castration-sensitive prostate cancer

    Akamatsu S., Naito Y., Nagayama J., Sano Y., Inoue S., Matsuo K., Sano T., Ishida S., Matsukawa Y., Kato M.

    Nagoya Journal of Medical Science   86 巻 ( 2 ) 頁： 169 - 180   2024年

    　詳細を見る

    記述言語：英語   出版者・発行元：Nagoya Journal of Medical Science  

    Androgen receptor signaling inhibitors combined with androgen deprivation therapy have become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC), regardless of tumor volume or risk. However, survival of approximately one-third of these patients has not improved, necessitating further treatment escalation. On the other hand, for patients with oligometastatic mCSPC, there is an emerging role for local radiation therapy. Although data remain scarce, it is expected that treatment of both primary tumor as well as metastasis-directed therapy may improve survival outcomes. In these patients, systemic therapy may be de-escalated to intermittent therapy. However, precise risk stratification is necessary for risk-based treatment escalation or de-escalation. In addition to risk stratification based on clinical parameters, research has been conducted to incorporate genomic and/or transcriptomic data into risk stratification. In future, an integrated risk model is expected to precisely stratify patients and guide treatment strategies. Here, we first review the transition of the standard treatment for mCSPC over the last decade and further discuss the newest concept of escalating or de-escalating treatment using a multi-modal approach based on the currently available literature.

    DOI： 10.18999/nagjms.86.2.169

    Scopus

    PubMed

  8. Efficacy of rehabilitation initiated in the early phase after simultaneous deceased donor liver and kidney transplantation: A case report Open Access

    Tanaka, S; Mizuno, Y; Nojiri, S; Futamura, D; Nagaya, M; Nishida, Y; Sano, Y; Ishida, S; Kato, M; Kurata, N; Jobara, K; Fujimoto, Y; Ogura, Y

    MEDICINE   102 巻 ( 38 ) 頁： e35324   2023年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：Medicine (United States)  

    Rationale: The purpose of this case report is to describe a case of successful early rehabilitation intervention for simultaneous liver and kidney transplantation (SLKT). Patient concerns: A 51-year-old Japanese man was diagnosed with Caroli disease 27 years ago. Hemodialysis was introduced due to end-stage renal disease 17 years ago. Diagnoses: After successful SLKT, the patient was extubated on postoperative day (POD) 1, liberated from dialysis on POD 4, and discharged from the intensive care unit on POD 9. Interventions: Supervised rehabilitation was started on POD 2, and the patient was able to walk 100 m on POD 9. Electrical muscle stimulation therapy was started to improve muscle weakness in both legs on POD 16, and aerobic exercise using a cycle-ergometer was started on POD 24. Outcomes: The 6-minute walking distance improved from 324 m on POD 14 to 501 m on POD 28. The patient could walk 4000 to 5000 steps per day at hospital discharge, and was discharged home on POD 32. There were no adverse events, including worsening hepatic or renal function, during the rehabilitation period. One month after discharge, the patient was able to perform 30 to 40 minutes of aerobic exercise every day, and returned to work 5 months after discharge. Lessons: This case shows that early rehabilitation intervention immediately after SLKT safely and rapidly improved physical performance without adverse events. The results in the present case suggest that regular physical assessment and appropriate interventions with a variety of exercise modalities can contribute to improved physical performance in SLKT patients.

    DOI： 10.1097/MD.0000000000035324

    Open Access

    Web of Science

    Scopus

    PubMed

  9. 腎移植後ガンシクロビル耐性サイトメガロウイルス感染となった2例

    佐野 優太, 石田 昇平, 佐野 友康, 加藤 真史, 田中 章仁, 齋藤 尚二, 安田 宜成, 丸山 彰一, 赤松 秀輔

    移植   58 巻 ( Supplement ) 頁： s274_2 - s274_2   2023年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本移植学会  

    <p>サイトメガロウイルス(CMV)感染症は最も頻度が高く重要な移植後ウイルス感染症である。治療にはまずガンシクロビル(GCV)、バルガンシクロビル(VGCV)が使用されるが、今回移植後GCV耐性CMV感染となり、ホスカルネットナトリウムにて治癒した2例を経験したので報告する。症例1:50代男性。X-17年より血液透析導入。Caroli病による頻回の胆管炎で入院を繰り返していた。ドナーは50代女性。原疾患は脳出血。脳死下肝腎同時移植施行。S-Cre1.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。CMV抗体陽性。術後7か月後、CMV感染となりVGCV内服開始。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。症例2:40代男性。X年、悪性高血圧による慢性腎不全にて血液透析導入。母親をドナーとした生体腎移植施行。S-Cre2.00mg/dl前後で安定し、特記合併症なく術後約一か月で退院となった。レシピエントCMV抗体陰性、ドナーCMV抗体陽性であったためVGCV予防内服を開始した。術後6か月後、CMV感染となりVGCV内服を治療量へ増やした。内服開始後もCMV感染の改善見られず、GCV耐性が判明しホスカルネットナトリウム投与開始。特記合併症なく治癒した。今回、移植後GCV耐性CMVに対してホスカルネットナトリムを使用し、特記問題なく治癒した症例を経験したので若干の文献的考察を加えて報告する。</p>

    DOI： 10.11386/jst.58.supplement_s274_2

    CiNii Research

  10. 生体腎移植ドナーにおける腎提供後のフォローアップの重要性

    安田 宜成, 田中 章仁, 齋藤 尚二, 加藤 規利, 小杉 智規, 佐野 優太, 加藤 真史, 丸山 彰一

    移植   58 巻 ( Supplement ) 頁： s248_3 - s248_3   2023年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本移植学会  

    <p>【目的】日本透析医学会の統計調査では慢性維持透析患者107 人（0.043％）が腎移植ドナーとしての腎提供ありと回答した。名古屋大学の生体腎移植ドナーの予後を調査した。</p><p>【方法】対象は1998年以降に名古屋大学で生体腎移植のため腎提供したドナー167名。内2020～22年に受診した138名の最終診察時のCKD重症度分類を調査した。受診がない29名について背景を調査した。</p><p>【結果】生体腎移植ドナーのGFR区分はG2:18名（13.0％）、G3a:74名（53.6％）、G3b:44名（31.9％）G4:2名（1.5％）、蛋白尿区分はA1:103名（74.6％）、A2:25名（18.1％）、A3:5名（3.6％）、未測定5名（3.6％）であった。G4の1名は73歳男性で腎提供前の2回の実測Ｃｃｒ平均は126.15ｍＬ/分であったが腎提供後に高血圧を合併し、腎提供後15年以上の経過で大動脈瘤手術を受けていた。残る1名は80歳女性で腎提供前の実測GFRは113.9で、腎提供後も10年以上安定していたが、急性腎障害後に腎機能が低下した。A3の4名では、腎提供前の高血圧合併2名、肥満1名だった。</p>

    DOI： 10.11386/jst.58.supplement_s248_3

    CiNii Research

  11. Caroli病(先天性多発肝内胆管拡張症)による難治性胆管炎,末期腎不全症例に肝腎同時移植を実施した1例 査読有り

    佐野優太

    日本臨床腎移植学会雑誌     2023年

    　詳細を見る

    担当区分：筆頭著者   記述言語：日本語  

  12. 脳死下肺移植後に生体腎移植を施行した1例

    佐野 優太, 近藤 洋平, 吉澤 賢祐, 中根 渉, 内藤 祐志, 佐野 友康, 松尾 かずな, 石田 昇平, 松川 宣久, 加藤 真史

    移植   57 巻 ( Supplement ) 頁： s371_2 - s371_2   2022年

    　詳細を見る

    記述言語：日本語   出版者・発行元：一般社団法人 日本移植学会  

    <p>レシピエント：40代男性。間質性肺炎のため、X-5年に脳死下両側肺移植施行後。免疫抑制剤としてMMF、TacER、Pred.内服中。徐々に腎機能悪化し、X-1年に血液透析導入。妹をドナーとした生体腎移植目的に当科受診。血液型不一致。AB 2mismatch　DR　1mismatch、CDC　T(-)Bw(-)Bc(-)、FCXM　T(-)B(-)、PRA screening　classⅠ(-)classⅡ(-)、導入免疫抑制剤：TacER+MMF+Pred.+BXM。右腸骨窩生体腎移植術施行。手術時間：3時間52分。外腸骨静脈-腎静脈、外腸骨動脈-腎動脈を吻合。尿管膀胱吻合は粘膜下トンネル3cm作成、Lich-Gregori法で縫合。術後速やかに腎機能発現し、S-Cre1.3mg/dl前後で推移。術後7か月拒絶反応なく、腎機能安定し経過している。両側肺移植後に生体腎移植を施行し、術後経過良好であったので若干の文献的考察を加え報告する。</p>

    DOI： 10.11386/jst.57.supplement_s371_2

    CiNii Research

▼全件表示

論文の先頭へ▲

講演・口頭発表等 6

  1. 当院における腎移植後悪性腫瘍の検討

    佐野優太

    第60回　日本移植学会総会  2024年9月14日 

    　詳細を見る

    開催年月日： 2024年9月

    会議種別：ポスター発表  

  2. 生体腎移植後早期にT細胞型拒絶反応を起こした1例

    佐野優太

    第39回腎移植・血管外科研究会  2024年6月13日 

    　詳細を見る

    開催年月日： 2024年6月

    会議種別：口頭発表（一般）  

  3. A Study of malignant tumors after transplantation in our hospital.

    2024年4月27日 

    　詳細を見る

    開催年月日： 2024年4月

    会議種別：ポスター発表  

  4. 腎がん治療指針(2024年) 招待有り

    佐野優太

    2024年4月12日 

    　詳細を見る

    開催年月日： 2024年4月

    記述言語：日本語   会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

  5. 生体腎移植

    佐野優太

    第33回腎移植勉強会  2024年3月16日 

    　詳細を見る

    開催年月日： 2024年3月

    会議種別：公開講演，セミナー，チュートリアル，講習，講義等  

  6. 献腎移植後に急速に進行した固有腎細胞癌の1例

    佐野優太

    第57回　日本臨床腎移植学会  2024年2月14日 

    　詳細を見る

    開催年月日： 2024年2月

    会議種別：口頭発表（一般）  

▼全件表示

講演・口頭発表等の先頭へ▲
 

担当経験のある科目 (本学) 1

  1. 泌尿器科

    2024

担当経験のある科目 (本学)の先頭へ▲